Showing 1765 results
-
Press release /In Phase III KITE study, Beovu (brolucizumab) 6 mg achieved its primary endpoint of non-inferiority to aflibercept 2 mg in mean change in best-corrected visual acuity (BCVA) at year one (week 52)1…
-
Press release /Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with…
-
Story /Novartis researchers are partnering with advocacy groups to understand the stigma and challenges facing patients with obesity.
-
Press release /The three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] Consistent improvement in RFS observed across all pre-specified…
-
Press release /Basel, December 6, 2021 — The bilateral transaction between Novartis and Roche for the sale of 53.3 million (approximately 33%) Roche bearer shares has successfully closed today, December 6, 2021.…
-
Press release /Study in partnership with the Alliance for Clinical Trials in Oncology is the first large controlled trial to show overall survival benefit in FLT3-mutated AML AML is the most common acute…
-
Press release /FLAME study showed consistent superiority of Ultibro® Breezhaler® over Seretide® across exacerbation outcomes, lung function and health-related quality of life in COPD patients Ultibro…
-
Press release /
Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with unrivaled OS evidence1Kisqali plus endocrine therapy had a median OS of nearly five years (58.7… -
Ad hoc release /Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies Key growth…